Table 4.
Incidence of the combined primary end point and of each of its various components, and all-cause death according to the ACE insertion/deletion polymorphism in the SURDIAGENE cohort
| Study end point | All patients |
ACE genotype
|
P value (log-rank): II vs. ID vs. DD | ||
|---|---|---|---|---|---|
| ACE II | ACE ID | ACE DD | |||
| n enrolled | 917 | 118 | 448 | 351 | |
| Primary combined end point | 187/7.28 (6.28–8.29) | 26/8.32 (5.26–11.39) | 90/7.11 (5.70–8.53) | 71/7.18 (5.57–8.78) | 0.769 |
| Cardiovascular death | 73/2.68 (2.07–3.28) | 15/4.57 (2.31–6.83) | 29/2.14 (1.37–2.91) | 29/2.77 (1.77–3.77) | 0.057 |
| Myocardial infarction (fatal and nonfatal) | 31/1.15 (0.75–1.55) | 5/1.53 (0.19–2.86) | 14/1.04 (0.50–1.59) | 12/1.16 (0.50–1.81) | 0.771 |
| Stroke (fatal and nonfatal) | 25/0.92 (0.56–1.28) | 3/0.91 (0.11–1.94) | 11/0.81 (0.33–1.30) | 11/1.06 (0.43–1.68) | 0.842 |
| Heart failure requiring hospitalization | 70/2.63 (2.02–3.23) | 11/3.45 (1.44–5.45) | 29/2.18 (1.40–2.97) | 30/2.95 (1.91–3.99) | 0.358 |
| ESRF | 26/0.97 (0.60–1.34) | 2/0.61 (0.03–1.46) | 15/1.13 (0.56–1.70) | 9/0.87 (0.30–1.43) | 0.633 |
| Death (all-cause) | 108/3.93 (3.20–4.65) | 20/6.04 (3.47–8.61) | 45/3.29 (2.34–4.23) | 43/4.08 (2.89–5.28) | 0.125 |
Data are n and number of events per 100 patient-years (95% CI). Primary combined end point: time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, nonfatal heart failure requiring hospitalization, or ESRF.